George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
|Articles|September 16, 2008
- June15 2004
- Volume 11
- Issue 11
Tricky Trip Tickets
Author(s)Michael Sheehan
Advertisement
Example:
The airlines don't like it and youmight get in trouble if you try it too often,but there's a sneaky way to save on airlinetickets called the "shadow stay." If an airline requires a Saturday night stay toqualify for cheap tickets, buy tworoundtrips with Saturday night stays,but use only the first half of each ticket. You have a mid-week meetingin Chicago. Buy a round trip ticket fromNew York to Chicago, leaving Tuesdayand returning Sunday. Then buy around-trip ticket from Chicago to NewYork, leaving Thursday and returningSunday. Use the first leg of the NewYork-Chicago ticket to fly out on Tuesdayand the first leg of the Chicago-NewYork ticket to return on Thursday.
Articles in this issue
about 18 years ago
Georgia: Walk Down the Antebellum Trailabout 18 years ago
Tarrytown Welcomes Weekend Film Criticsabout 18 years ago
Land Rover Discovery 3:In Style and Off-Roadabout 18 years ago
Customize Your Own Investing Approachabout 18 years ago
Martha's Lesson: Be Careful with Tipsabout 18 years ago
School Your Children on the Stock Marketabout 18 years ago
Recite the ABCs of the Share Classesabout 18 years ago
Offset Volatility with Some Clever Varietyabout 18 years ago
Model Portfolio Series: Equity Incomeabout 18 years ago
Beat the Heat of the Rising Interest RatesAdvertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
3
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5